Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by interference with neuromuscular transmission by autoantibodies against the nicotinic acetylcholine receptor (AChR) on muscle. Previously, we have shown that two peptides, denoted RhCA 67-16 and RhCA 611-001, designed to be complementary in structure to the main immunogenic region and the dominant Lewis rat T cell epitope (α-chain residues 100-116) of the AChR, respectively, are effective vaccines that prevent EAMG in rats by inducing anti-idiotypic/clonotypic antibodies (Ab) and lowering levels of AChR Ab. These studies employed keyhole limpet hemocyanin (KLH) as a carrier and complete Freunds adjuvant (CFA). In advance of a clinical trial the present study tested the efficacy of RhCA 611-001 when combined with different adjuvants that are approved for use in humans. Adjuvants chosen for comparison were incomplete Freunds adjuvant (IFA) and aluminum hydroxide (Alum). As a second goal we evaluated diphtheria toxin (DT) as an alternative carrier protein to KLH. Alum was found to be an effective adjuvant, particularly when used with the peptide conjugated to DT. This combination of carrier and adjuvant provided protection against EAMG comparable with that observed with CFA and KLH. Using enzyme-linked immunosorbent assays for Ab against RhCA 611-001, it was found that disease protection is qualitatively, but not quantitatively, related to the anti-peptide Ab response. Our results demonstrate a vaccine formulation that should be useful in the first soon-to-be-conducted clinical trials of peptide vaccines to specifically correct aberrant T and B cell responses in an autoimmune disease.
PatrickJ, LindstromJ.Autoimmune response to acetylcholine receptor. Science180:871–872, 1973.
2.
EngelAG, SahashiKI, FumigalliG.The immunopathology of acquired myasthenia gravis. Ann N Y Acad Sci377:158–174, 1981.
3.
SmithLR, BostKL, BlalockJE. Generation of idiotypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNA: A possible molecular basis for the network theory. J Immunol138:7–9, 1987.
4.
BlalockJE, WhitakerJN, BenvenisteEN, BostKL. Use of peptides encoded by complementary RNA for generating anti-idiotypic antibodies of predefined specificity. Methods Enzymol178:63–74, 1989.
5.
BlalockJE. Genetic origins of protein shape and interaction rules. Nat Med1:876–878, 1995.
6.
VillainM, JacksonPL, ManionMK, DongW-J, SuZ, FassinaG, JohnsonTM, SakaiTT, KrishnaNR, BlalockJE. De novo design of peptides targeted to the EF hands of calmodulin. J Biol Chem274:2676–2685, 2000.
7.
BaranyiL, CampbellW, OhshimaK, FujimotoS, BorosM, OkadaH.The antisense homology box: A new motif within proteins that encodes biologically active peptides. Nat Med1:894–901, 1995.
8.
CrawfordSE, StellmachV, Murphy-UllrichJE, RibeiroSMF, LawlerJ, HynesRO, BoivinGP, BouckN.Thrombospondin-1 is a major activator of TGF-beta 1 in vivo. Cell93:1159–1170, 1998.
9.
RibeiroSMF, PoczzatekM, Schultz-CherryS, VillainM, Murphy-UllrichJE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem274:13586–13593, 1999.
10.
GhisoJ, SaballE, LeoniJ, RostagnoA, FrangioneB.Binding of cystatin C to C4: The importance of sense-antisense peptides in their interaction. Proc Natl Acad Sci U S A87:1288–1291, 1990.
11.
PallaE, BensiG, SolitoE, BuonamassaDT, GassinaG, RaugeiG, SpanoF, GaleottiC, MoraM, DomenighiniM, RossiniM, GalloE, VarinciV, BugnoliM, BertiniF, ParenteL, MelliM.Loop substitution as a tool to identify active sites of interleukin-l-beta. J Biol Chem268:13486–13492, 1993.
12.
Ruiz-OpazoN, AkimotoK, HerreraVLM. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat Med1:1074–1081, 1995.
13.
WhitakerJN, SparksBE, WalkerDP, GoodinR, BenvenisteEN. Monoclonal idiotypic and anti-idiotypic antibodies produced by immunization with peptides specified by a region of human myelin basic protein mRNA and its complement. J Neuroimmunol22:157–166, 1989.
14.
ZhouSR, HanQ, LaGankeCC, WhitakerJN. Comparison of properties of murine monoclonal anti-idiotypic antibodies generated with idiotype-bearing monoclonal antibodies to myelin basic protein peptides or their complementary peptides. Clin Immunol Immunopathol70:251–259, 1994.
15.
ZhouSR, WhitakerJN. Use of complementary peptides and their antibodies in T-cell-mediated autoimmune disease: Experiments with myelin basic protein. ImmunoMethods5:136–147, 1994.
16.
ZhouSR, WhitakerJN. Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol150:1629–1642, 1993.
17.
ZhouSR, WhitakerJN, HanQ, MaierC, BlalockJE. A cross-reactive idiotope on T cells from PL/J mice and Lewis rats that recognizes different myelin basic protein encephalitogenic epitopes but is restricted by TCR V beta 8.2. J Immunol153:2340–2351, 1994.
18.
AragaS, LeBoeufRD, BlalockJE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc Natl Acad Sci U S A90:8747–8751, 1993.
19.
AragaS, GalinFS, KishimotoM, AdachiA, BlalockJE. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptor. J Immunol157:386–392, 1996.
20.
BoquetD, DeryO, FrobertY, GrassiJ, CouraudJY. Is hydropathic complementarity involved in antigen-antibody binding?Mol Immunol32:303–308, 1995.
21.
BostKL, SmithEM, BlalockJE. Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc Natl Acad Sci U S A82:1372–1375, 1985.
22.
DeryO, FrobertY, ZerariF, CreminonC, GrassiJ, FischerJ, ConrathM, CouraudJ-Y. A monoclonal antibody to the ligand-binding domain of the neurokinin 1 receptor (NK1-R) for the neuropeptide substance P. J Neuroimmunol76:1–9, 1997.
23.
MartinsVR, GranerE, Garcia-AbreuJ, deSouzaSJ, MercadanteAF, VeigaSS, ZanataSM, NetoVM, BrentaniRR. Complementary hydropathy identifies a cellular prion protein receptor. Nat Med3:1376–1382, 1997.
24.
McGuiganJE. Antibodies to complementary peptides as probes for receptors. ImmunoMethods5:158–166, 1994.
25.
BlalockJE. Complementarity of peptides specified by “sense” and “antisense” strands of DNA. Trends Biotechnol8:140–144, 1990.
26.
BorovskyD, PowellCA, NayarJK, BlalockJE, HayesTK. Characterization and localization of mosquito-gut receptors for trypsin modulating oostatic factor using a complementary peptide and immunocytochemistry. FASEB J8:350–355, 1994.
27.
PascualDW, BostKL. Anti-peptide antibodies recognize antisubstance P antibodies in an idiotypic fashion. Peptide Res2:207–212, 1989.
28.
AragaS, XuL, NakashimaK, VillainM, BlalockJE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J14:185–196, 2000.
29.
SheltonGD, CardinetGHIII, LindstromJM. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology38:1417–1423, 1988.
30.
SheltonGD, WillardMD, CardinetGHIII, LinstromJ.Acquired myasthenia gravis. J Vet Int Med4:281–284, 1990.
31.
FroehnerSC, RaftoS.Comparison of the subunits of Torpedo californica acetylcholine receptor by peptide mapping. Biochemistry18:301–307, 1979.
32.
WofsyL, BurrB.The use of affinity chromatography for the specific-purification of antibodies and antigens. J Immunol103:380–382, 1969.
33.
LennonVA, LindstromJM, SeyboldME. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med141:1365–1375, 1975.
34.
ShouE, AfsharA.Comparison of Freund's adjuvant and TiterMax in inducing anti-idiotype to idiotypic antibodies against pseudorabies virus antigens. Vet Immunol Immunopathol48:113–122, 1995.
35.
KahnCR, McIntoshKR, DrachmanDB. T-cell Vaccination in experimental myasthenia gravis: A double-edged sword. J Autoimmunity3:659, 1990.
36.
SpackEG. Treatment of autoimmune diseases through manipulation of antigen presentation. Crit Rev Immunol17:529, 1997.
37.
KarachunskiPI, OstlieNS, OkitaDR, Conti-FineBM. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J Clin Invest15:3027, 1997.
38.
SelaM.Specific vaccines against autoimmune diseases. CR Acad Sci III322:933, 1999.
39.
AragaS, KishimotoM, DoiS, NakashimaK.A complementary peptide vaccine that induces T cell anergy and prevents experimental allergic neuritis in Lewis rats. J Immunol163:476–482, 1999.
